Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.

Shigeyoshi Iwamoto; Shoichi Hazama; Takeshi Kato; Yasuhiro Miyake; Mutsumi Fukunaga; Chu Matsuda; Hiroyuki Bando; Junichi Sakamoto; Koji Oba; Hideyuki Mishima

首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.

【24h】

Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.

机译：克拉野生型转移性结肠直肠癌中二线甲磺酸/ 5-氟尿嘧啶/伊立替康（FOLFIRI）的多中心期II研究：倍二手研究。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Second-line cetuximab plus FOLFIRI was effective and well-tolerated.

机译：二线Cetuximab Plus Folfiri有效且耐受良好。

著录项

来源
《Anticancer Research: International Journal of Cancer Research and Treatment》 |2014年第4期|共7页
作者
Shigeyoshi Iwamoto; Shoichi Hazama; Takeshi Kato; Yasuhiro Miyake; Mutsumi Fukunaga; Chu Matsuda; Hiroyuki Bando; Junichi Sakamoto; Koji Oba; Hideyuki Mishima;
展开▼
作者单位

Department of Surgery Kansai Medical University Takii Hospital 10-15 Fumizono-cho Moriguchi-city;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. CMAB009联合伊立替康或伊立替康单药二线治疗氟嘧啶和奥沙利铂治疗失败的KRAS野生型转移性结直肠癌患者的研究:一项前瞻性、开放、随机、Ⅲ期试验 [J] . 石远凯, 白丽, 张沂平, 癌症（英文版） . 2020,第007期
2. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. [J] . Shigeyoshi Iwamoto, Shoichi Hazama, Takeshi Kato, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第4期

机译：克拉野生型转移性结肠直肠癌中二线甲磺酸/ 5-氟尿嘧啶/伊立替康（FOLFIRI）的多中心期II研究：倍二手研究。
3. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) [J] . J Souglakos, N Androulakis, K Syrigos, British Journal of Cancer . 2006,第6期

机译：FOLFOXIRI（亚叶酸，5-氟尿嘧啶，奥沙利铂和伊立替康）与FOLFIRI（亚叶酸，5-氟尿嘧啶和伊立替康）作为转移性结直肠癌（MCC）的一线治疗：来自希腊肿瘤研究组的多中心随机III期试验（霍格）
4. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study [J] . Jean-Luc Raoul, Jean-Luc Van Laethem, Marc Peeters, BMC Cancer . 2009,第1期

机译：西妥昔单抗联合伊立替康/ 5-氟尿嘧啶/亚叶酸（FOLFIRI）在转移性结直肠癌的初始治疗中：一项多中心的两部分I / II期研究
5. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
6. Use and outcomes of newer chemotherapeutic agents in colorectal cancer patients using Irinotecan as a case study. [D] . Obeidat, Nour A. 2008

机译：以伊立替康为例的结直肠癌患者中新型化疗药物的使用和结果。
7. FOLFOXIRI (folinic acid 5-fluorouracil oxaliplatin and irinotecan) vs FOLFIRI (folinic acid 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) [O] . J Souglakos, N Androulakis, K Syrigos, 2006

机译：FOLFOXIRI（亚叶酸5-氟尿嘧啶奥沙利铂和伊立替康）与FOLFIRI（亚叶酸5-氟尿嘧啶和伊立替康）作为转移性结直肠癌（MCC）的一线治疗：来自希腊肿瘤研究组的多中心随机III期试验（霍格）
8. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. [O] . Raoul, Jean-Luc, Van Laethem, Jean-Luc, Peeters, Marc, 2009

机译：西妥昔单抗联合伊立替康/ 5-氟尿嘧啶/亚叶酸（FOLFIRI）在转移性结直肠癌的初始治疗中：一项多中心的两部分I / II期研究。

Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.

摘要

著录项

相似文献

相关主题

期刊订阅